Compare Humana Inc (HUM) vs RLX Technology Inc (RLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs RLX Technology Inc — how do they compare? Humana Inc trades at $436.33 (market cap $46.49B), while RLX Technology Inc trades at $1.72 (market cap $2.10B). The key difference: Humana Inc is far larger — about 22.1× RLX Technology Inc's market cap, and RLX Technology Inc pays the higher dividend (5.81%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and RLX Technology Inc for 34 Days on average.
| HUM | RLX | |
|---|---|---|
Market Cap | $46.49B | $2.10B |
Volume | 2,567,704 | 1,079,706 |
Sector | Health | Consumer Staples |
52-Week High | $409.85 | $2.57 |
52-Week Low | $163.67 | $1.68 |
Typical Hold Time | 53 Days | 34 Days |
Enterprise Value | $53.84B | $832.26M |
Dividend Yield | 0.91% | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $441.74, up 11.41% over 24 hours, reflecting strong momentum. The stock shows bullish technical signals with support at $391 and resistance at $406. Fundamentally, revenue grew to $129.66B in 2025, though net income margin compressed to 0.88%. Recent news highlights a Barclays upgrade to a $515 price target and upcoming Q3 earnings on November 6, 2026.
The outlook is cautiously optimistic with a consensus price target of $457.05 implying modest upside. Risks include margin pressure from Medicare Advantage plan changes and potential regulatory scrutiny. Institutional activity is mixed, with Bank of America adding a position while some funds reduced stakes.
RLX Technology trades at $1.73, showing no change in the latest session and recently hitting 52-week lows. The stock exhibits bearish technical signals with mixed fundamentals - revenue grew to $3.62B in 2025 with strong 21.87% net margins, but recent quarters show consistent earnings misses. Analyst coverage remains limited with a single hold rating, while cash flow trends show volatility with negative net cash flow in 2025.
RLX faces near-term headwinds from earnings underperformance and technical weakness, though valuation appears reasonable with P/E of 15.46 and P/B below 1.0. International expansion provides growth potential, but regulatory risks and margin compression require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About RLX Technology Inc
RLX Technology Inc. is a leading e-vapor company in China, focusing on the research, development, and sale of e-vapor products. The company primarily operates under the RELX brand, offering a range of closed-system e-vapor products designed to deliver a high-quality user experience. RLX's business model is centered on product innovation, strong brand building, and a vast distribution network across China.
Read more on RLX →
